Roxanne Lagano Sells 326 Shares of Zoetis Inc. (NYSE:ZTS) Stock

by · The Markets Daily

Zoetis Inc. (NYSE:ZTS – Get Free Report) EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Roxanne Lagano also recently made the following trade(s):

  • On Tuesday, February 11th, Roxanne Lagano sold 326 shares of Zoetis stock. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68.

Zoetis Price Performance

Zoetis stock traded down $7.41 during mid-day trading on Tuesday, hitting $164.39. The company’s stock had a trading volume of 3,510,886 shares, compared to its average volume of 2,578,671. The stock has a market capitalization of $73.61 billion, a P/E ratio of 30.05, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The stock’s fifty day moving average price is $166.91 and its two-hundred day moving average price is $176.66. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ZTS shares. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $215.90.

Get Our Latest Stock Analysis on Zoetis

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Callahan Advisors LLC lifted its position in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares in the last quarter. Pensionfund Sabic raised its stake in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. CIBC Asset Management Inc lifted its holdings in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. PFW Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $1,764,000. Finally, Alberta Investment Management Corp grew its holdings in shares of Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after buying an additional 28,700 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories